The Best CEO in Pharma

Discussion in 'Acorda Therapeutics' started by anonymous, Dec 4, 2018 at 6:47 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Pathetic. There really should be a lawsuit regarding the mismanagement of the company. There are no products left to speak of (how much did the big price hike on the only marketed drug account for the revised quarterly earnings estimate?), so many people have been let go or laid off, and there are a bunch of idiots who couldn’t spell “manufacture” but reaped huge bonuses and titles while convincing the CEO that the inhaled levodopa can actually be approved. Ron and The Street should have known better years ago when the laughable caliber of the plant and workers added via the merger-acquisition became clear. And if they did know better, then they’ve misled investors and shareholders (including employees). What a shame
     

  2. anonymous

    anonymous Guest

    In a generally down day on the Street, our ACOR is blasting upwards .44% as of now. That's a vote of confidence in our company and our Leadership / CEO. So when Inbrija gets the OK in January the trajectory of rebound will accelerate and the future looks great !
     
  3. anonymous

    anonymous Guest

    Habib it’s still at $16. Save your little dance party until the stock actually moves a more than .05

    You seem desperate for anything you can spin positive these days.
     
  4. anonymous

    anonymous Guest

    marketing and training suck here. wake up and get real people! I'm leaving this crap company soon I hope.
     
  5. anonymous

    anonymous Guest

    You obviously have not had the Six Sigma training !
     
  6. anonymous

    anonymous Guest

    Lets try to have a civil and objective conversation. Clearly inhaled levodopa will be a blockbuster. Available as a generic drug for years at pennies a dose, Ron had a brilliant insight, nobody else ever heard about pulmonary delivery. Ron read about Pfizer's inhaled insulin and immediately started inhaled levodopa. Talk about genius moves, Pfizer continues to benefit from the blockbuster status of inhaled insulin. Soon Acorda will be similarly benefiting from inhaled levodopa. Actually the only thing that will happen is folks will finally understand why "dopa" is so important.
     
  7. anonymous

    anonymous Guest

    Habib, you really need to do some research before you blather on about inhaled insulin.

    Exubera was a colossal failure and Pfizer basically walked away from it. The failure was so total that other inhaled insulin’s in development at other companies were abandoned in development. Sanofi was stupid enough to try again with Mannkinds product and failed miserably as well.

    IF inhaled LD even gets approved, you will begin to see the challenges with this “novel” approach. Of course then you will rant about the sales force not doing the bidding of VelociRon.
     
  8. anonymous

    anonymous Guest

    Yes our sales force must be adequately trained you know that as does our CEO! As it is projected by HQ to be approved in Jan the sales team must step up!! No excuses !!! Maybe Six Sigma will be necessary to infuse sales passion. Pfizer screwed up due to inferior sales team job!
     
  9. anonymous

    anonymous Guest

    Well there you have it folks. Straight from RCs ministry of propaganda.

    You are about to be handed a turd and expected to make it a golden egg. The forecast is grossly overstated and doesn’t represent the market opportunity (Turkmenistan aside), but represents what RC “needs” to keep his company and image afloat.

    I hope all ACOR associates are prepared for the ride.
     
  10. anonymous

    anonymous Guest

    Maybe google the history of Acorda...Ron did not start inhaled L-Dopa (so not a genius move there from him), it was started by Alkermes (or even further back, AIR) who spun off the inhalation technology to a startup call Civitas Therapeutics which Acorda purchased in 2014. So before giving credit to @RonCohensHair you might want to get your facts straight...
     
  11. anonymous

    anonymous Guest

    The info you posted was misleading. Dr Cohen was at the forefront of this technology and will be heralded again as one of the best CEOs in pharma. Hopefully his head will not swell up too much...we don't want him to be recruited by another company.
     
  12. anonymous

    anonymous Guest

    It was a very smart move on Ron and his Senior Management Team to acquire Civitas, NO DOUBT.

    However, that does NOT give "the Ministry of Propaganda" the right to re-write history.
    Acorda's ex-Chief Tech Officer, Rick Batycky, was one of the smart brains behind inhaled levodopa, not Ron.

    Get it straight and stop the Fake News
     
  13. anonymous

    anonymous Guest

    the ex CTO did a very good job advising our Leader. OK agree. But still the butt stops at the corner office, as they say, and Dr Cohen made it happen.
     
  14. anonymous

    anonymous Guest

    exactly, Dr Cohen made it happen. Took over the filing after the intern fiasco. Held all accountable and then pulled off the approval. Great Leader.
     
  15. anonymous

    anonymous Guest

    Dr Cohen made it happen.
     
  16. anonymous

    anonymous Guest

    Habib, you must be making bank this holiday season with your VelociRon love fest.

    There is still a flaw in your adulation. If Ronnie is to be commended for this belated triumph, then he is also to be held accountable for a) being a year behind in approval, b) poor IP strategy and c) multiple failed programs.

    The best CEOs in Pharma don’t have a stock near the bottom of its five year value going into a “ballbuster” launch. They also don’t need to employ cheap labor with a poor understanding of the industry coupled with a rudimentary understanding of the language to pump their image. Usually performance speaks for itself. In lieu of said performance, I guess you have a pretty stable career being the equivalent of a sideshow barker for old Ronnie.
     
  17. anonymous

    anonymous Guest

    When we are ballbusting our launch we know we are in Dr Ron’s. His leading us in approval is why he is #1. It must have been a sad day when you were asked to leave the Company. Maybe you should now leave Cafepharma and let us continue our ballbusting. Acorda is on a major rise and we know that product release is set for launch. You may find happiness looking to you own path.
     
  18. anonymous

    anonymous Guest

    *****************
    The above post, obviously from an Acordian, is right on the mark. We have a great Leader in Dr RC, an innovative genius (fyi Mensa certified). We refer to our new products as 'ballbusters', as they will squeeze out the competition. (This soon to be trademark protected.) Lets start 2019 with a round of celebrations for the Acordian Team. That's EVERYONE !! Lets GO GO GO ! ! ! !
    ******************